Form 8-K · Current Report · Filed 2026-04-30
Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Collaborations
Alnylam Pharmaceuticals, Inc. reported its first quarter 2026 financial results, achieving global net product revenues of $1,036 million, a 121% growth compared to Q1 2025. The company's TTR franchise, particularly AMVUTTRA, drove this growth with total TTR revenues of $910 million, a 153% increase year-over-year. Alnylam reiterated its 2026 financial guidance, expecting combined net product revenues between $4,900 million and $5,300 million. Additionally, the company announced new strategic collaborations with Viz.ai and the American Heart Association aimed at improving diagnosis and care for ATTR-CM patients.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001628280-26-028601
- CIK
- 0001178670
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$301.19
Next session
-1.7%
Since filing
-31.8%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ALNY insiders reported 28 Form 4 transactions — net selling of $356K.
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.